title: Tumor vasculature targeting and imaging in living mice with reduced graphene oxide.
abstract: Graphene-based nanomaterials have attracted tremendous attention in the field of biomedicine due to their intriguing properties. Herein, we report tumor vasculature targeting and imaging in living mice using reduced graphene oxide (RGO), which was conjugated to the anti-CD105 antibody TRC105. The RGO conjugate, (64)Cu-NOTA-RGO-TRC105, exhibited excellent stability in vitro and in vivo. Serial positron emission tomography (PET) imaging studies non-invasively assessed the pharmacokinetics and demonstrated specific targeting of (64)Cu-NOTA-RGO-TRC105 to 4T1 murine breast tumors in vivo, compared to non-targeted RGO conjugate ((64)Cu-NOTA-RGO). In vivo (e.g., blocking 4T1 tumor uptake with excess TRC105), in vitro (e.g., flow cytometry), and ex vivo (e.g., histology) experiments confirmed the specificity of (64)Cu-NOTA-RGO-TRC105 for tumor vascular CD105. Since RGO exhibits desirable properties for photothermal therapy, the tumor-specific RGO conjugate developed in this work may serve as a promising theranostic agent that integrates imaging and therapeutic components.
authors: Materials Science Program, University of Wisconsin-Madison, Madison, WI 53705-2275, USA.
authors: Sixiang
authors: S
authors: Shi
authors: Kai
authors: K
authors: Yang
authors: Hao
authors: H
authors: Hong
authors: Hector F
authors: HF
authors: Valdovinos
authors: Tapas R
authors: TR
authors: Nayak
authors: Yin
authors: Y
authors: Zhang
authors: Charles P
authors: CP
authors: Theuer
authors: Todd E
authors: TE
authors: Barnhart
authors: Zhuang
authors: Z
authors: Liu
authors: Weibo
authors: W
authors: Cai
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D005434:Flow Cytometry; D006108:Graphite; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply*; D051379:Mice; D049268:Positron-Emission Tomography
chemical_list: D006108:Graphite
references: Science. 2009 May 15;324(5929):875-7
references: 19443761
references: J Am Chem Soc. 2011 May 4;133(17):6825-31
references: 21476500
references: Nanomedicine (Lond). 2011 Feb;6(2):317-24
references: 21385134
references: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references: 18758474
references: Nat Nanotechnol. 2007 Jan;2(1):47-52
references: 18654207
references: Am J Nucl Med Mol Imaging. 2012 Jan 1;2(1):1-13
references: 22229128
references: Small. 2011 Jul 18;7(14):1876-902
references: 21630440
references: Science. 2008 Feb 29;319(5867):1229-32
references: 18218865
references: Am J Nucl Med Mol Imaging. 2011;1(1):47-53
references: 23133794
references: Nat Mater. 2007 Mar;6(3):183-91
references: 17330084
references: ACS Nano. 2011 Jan 25;5(1):516-22
references: 21162527
references: Nanoscale. 2012 Jul 7;4(13):3833-42
references: 22653227
references: Chem Soc Rev. 2013 Jan 21;42(2):530-47
references: 23059655
references: Biomaterials. 2012 Jun;33(16):4147-56
references: 22386918
references: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references: 15688077
references: Science. 2004 Oct 22;306(5696):666-9
references: 15499015
references: Nature. 2012 Oct 11;490(7419):192-200
references: 23060189
references: Chem Soc Rev. 2010 Nov;39(11):4146-57
references: 20623061
references: Adv Mater. 2012 Apr 10;24(14):1868-72
references: 22378564
references: Nat Rev Cancer. 2002 Sep;2(9):683-93
references: 12209157
references: Nat Nanotechnol. 2007 Dec;2(12):751-60
references: 18654426
references: Small. 2007 Nov;3(11):1840-54
references: 17943716
references: Nat Protoc. 2008;3(1):89-96
references: 18193025
references: ACS Nano. 2012 Mar 27;6(3):2361-70
references: 22339280
references: Clin Cancer Res. 2008 Apr 1;14(7):1931-7
references: 18381930
references: Nano Lett. 2006 Apr;6(4):669-76
references: 16608262
references: Am J Transl Res. 2012;4(3):333-46
references: 22937210
references: Am J Nucl Med Mol Imaging. 2011;1(1):54-62
references: 23133795
references: J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S
references: 18523069
references: Curr Drug Deliv. 2011 Jan;8(1):135-43
references: 21034418
references: Am J Nucl Med Mol Imaging. 2012;2(1):55-76
references: 23133802
references: PLoS One. 2011;6(12):e28005
references: 22174762
references: Biomaterials. 2011 Jan;32(1):144-51
references: 20888630
references: Am J Nucl Med Mol Imaging. 2011;1(1):63-4
references: 23133796
references: J Nucl Med. 2007 Nov;48(11):1862-70
references: 17942800
references: Nucl Med Biol. 2011 Jan;38(1):29-38
references: 21220127
references: Cell. 2000 Jan 7;100(1):57-70
references: 10647931
references: Int J Clin Exp Med. 2011;4(1):32-42
references: 21394284
references: Clin Cancer Res. 2012 Sep 1;18(17):4820-9
references: 22767667
references: J Cell Biol. 2010 Mar 22;188(6):759-68
references: 20231381
references: Mol Pharm. 2012 Aug 6;9(8):2339-49
references: 22784250
references: Nano Today. 2009 Oct 1;4(5):399-413
references: 20161038
references: Nat Biotechnol. 2007 Oct;25(10):1165-70
references: 17891134
references: Am J Nucl Med Mol Imaging. 2012;2(1):33-47
references: 23133801
references: Cardiovasc Res. 2010 Apr 1;86(1):12-9
references: 19812043
references: Biomaterials. 2012 Mar;33(7):2206-14
references: 22169821